Dermatitis herpetiformis
ICD-10 L13.0 is a billable code used to indicate a diagnosis of dermatitis herpetiformis.
Dermatitis herpetiformis is a chronic autoimmune skin condition characterized by intensely itchy, blistering skin lesions, primarily affecting the elbows, knees, scalp, and buttocks. It is associated with gluten sensitivity and is often linked to celiac disease, although not all patients with dermatitis herpetiformis have gastrointestinal symptoms. The condition arises from an abnormal immune response to gluten, leading to the deposition of IgA antibodies in the dermal papillae, which triggers an inflammatory response. Clinically, patients present with grouped vesicles on an erythematous base, often resembling herpes simplex lesions. Disease progression can lead to chronic skin changes, including scarring and pigmentation alterations. Diagnosis is typically confirmed through skin biopsy, which reveals granular IgA deposits, and serological tests for anti-tissue transglutaminase antibodies. Management includes a strict gluten-free diet, which can significantly reduce symptoms and prevent recurrence. Topical corticosteroids and dapsone may be used for symptomatic relief.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L13.0 specifically covers dermatitis herpetiformis, a skin manifestation of gluten sensitivity, characterized by pruritic vesicular lesions. It is distinct from other dermatitis types and is often associated with celiac disease.
L13.0 should be used when the patient presents with the characteristic symptoms of dermatitis herpetiformis, particularly when there is a confirmed association with gluten sensitivity or celiac disease, differentiating it from other dermatitis codes.
Documentation should include clinical findings of vesicular lesions, serological tests for anti-tissue transglutaminase antibodies, and biopsy results showing IgA deposits. A detailed dietary history is also essential.
